Клинические рекомендации Гнездная алопеция

24. Luggen P., Hunziker T. High-dose intravenous corticosteroid pulse therapy in alopecia areata: own experience compared with the literature. J Dtsch Dermatol Ges. 2008 May; 6 (5):375-8. doi: 10.1111/j.1610-0387.2007.06608.x. Epub 2008 Jan.

25. Assouly P., Reygagne P., Jouanique C. et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata: An open study of 66 patient. [Article in French]. Ann Dermatol Venereol 2003; 130(3): 326-330.
26. Kurosawa M., Nakagawa S., Mizuashi M., et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006; 212(4):361-5.
27. Bin Saif G. A., Al-Khawajah M. M., Al-Otaibi H. M et al. Efficacy and safety of oral mega pulse methylprednisolone for severe therapy resistant Alopecia areata. Saudi Med J. 2012 Mar;33(3):284-91.
28. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55: 632-636.
29.Royer M., Bodemer C., Vabres P. et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol 2011;165(2):407-10.
30. Phan K., Ramachandran V., Sebaratnam D.F. Methotrexate for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019 Jan;80(1):120-127.e2. doi: 10.1016/j.jaad.2018.06.064. Epub 2018 Jul 10.
31. Jang Y. H., Kim S. L., Lee K. C. A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata. Ann Dermatol. 2016 Oct;28(5):569-574. Epub 2016 Sep 30.
32. Açıkgöz G., Calışkan E., Tunca M. The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol. 2014 Sep; 33(3):247-52. doi: 10.3109/15569527.2013.839997. Epub 2013 Oct 22.
33. Kennedy Crispin M., Ko J.M., Craiglow B. G et al. JCI Insight. 2016 Sep 22; 1(15):e89776. doi: 10.1172/jci.insight.89776. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
34. Almutairi N., Nour T. M., Hussain N. H. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Dermatology. 2019; 235(2):130-136. doi: 10.1159/000494613. Epub 2018 Dec 19.
35. Liu L. Y, Craiglow B. G., Dai F. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017 Jan; 76(1):22-28. doi: 10.1016/j.jaad.2016.09.007. Epub 2016 Nov 2.
36. Phan K., Sebaratnam D. F. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 May;33(5):850-856. doi: 1037. Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987; 16:745-748.
38. Fiedler-Weiss V. C., West D. P, Buys C. M. et al. Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol 1986;122(2):180-182.
39. Tosti A., Piraccini B. M, Pazzaglia M et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49:96-98.
40. Lassus A., Eskelinen A., Johansson E. Treatment of alopecia areata with three different PUVA modalities. Photodermatology 1984; 1:141-144.
41. Van der Schaar W.W., Sillevis Smith J.H. An evaluation of PUVA-therapy for alopecia areata. Dermatologica 1984; 168:250-252.
42. Mitchell A. J., Douglass M. C. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985; 12:644-649.
43. Taylor C. R., Hawk J. L. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol 1995; 133:914-918.
44. Healy E., Rogers S. PUVA treatment for alopecia areata - does it work? A retrospective review of 102 cases Br J Dermatol 1993; 129:42-44.
45. Freire P. C. B., Riera R., Martimbianco A. L. C., Petri V., Atallah A. N. Minoxidil for patchy alopecia areata: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 Mar 5. doi: 10.1111/jdv.15545.
46. Mohamed Z., Bhouri A., Jallouli A., et al. Alopecia areata treatment with a
phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol
Venereol. 2005;19:552-555.
47. Kamel M. M., Salem S. A., Attia H. H. Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8-methoxypsoralen application. Photodermatol Photoimmunol Photomed. 2011;27:45-50.
48. Al-Gurairi F., Al-Waiz M., Sharquie K. E. Oral zinc sulphate in the treatment of recalcitrant viral warts: Randomized placebo controlled trial. Br J Dermatol 2002; 146: 423-431.
49. Sharquie K. E., Najim R. A. , Al-Dori W. S. et al. Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study. J Dermatol 2006: 33: 541-546.
50. Ead R. D. Oral zinc sulphate in alopacia areata-a double blind trial. Br J Dermatol 1981: 104: 483-484.
51. Kubeyinje E. P. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994; 71: 674-675.
52. Abell E., Munro D. D. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973; 88:55-59.
53. Shapiro J., Price V. H. Hair regrowth. Therapeutic agents. Dermatol Clin 1998: 16: 341-356.
54. Chang K. H, Rojhirunsakool S., Goldberg L. J. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009: 8: 909-912.
55. Shapiro J., Madani S. Alopecia areata: Diagnosis and management. Int J Dermatol 1999; 38 (Suppl 1): 19-24.
56.Porter D., Burton J.L. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971; 85:272-273.
57. Sohn K. C., Jang S., Choi D.K. et al. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem Biophys Res Commun 2007: 356: 810-815.
58. Gregoriou S., Kazakos С., Rigopoulos D. Treatment options for alopecia areata, Expert Review of Dermatology 2011, 6:5, 537-548.
59. Price V. H. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16: 730-736.
60. Olsen E.A., Carson S.C., Turney E. A.. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128(11): 1467-1473.
61. Gill K. A., Baxter D. L. Alopecia totalis. Treatment with fluocinolone acetonide. Arch Dermatol 1963; 87: 384-386.
62. Pascher F., Kurtin S., Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970; 141(3): 193-202.
63. Mancuso G., Balducci A., Casadio C. et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003; 42: 572-575.
64. Ucak H., Kandi B., Cicek D. et al. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatolog Treat. 2012 Dec;23(6):410-20. doi: 10.3109/09546634.2011.590788. Epub 2011 Jul 25.
65. Sotiriou E. et al. Tacrolimus ointment 0.1% in the treatment of active patchy alopecia areata of childhood  European Journal of Pediatric Dermatology 17(4):227-230.
66. Vila T., Camacho Martinez F. Bimatoprost in the Treatment of Eyelash Universalis Alopecia Areata. Int J Trichology. 2010 Jul-Dec; 2(2): 86–88. doi: 10.4103/0974-7753.77511

67. Roseborough I., Lee H., Chwalek J. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 2009 Apr;60(4):705-6. doi: 10.1016/j.jaad.2008.08.029.

68. Mlacker S., Aldahan A.S., Simmons B.J. et al. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017 Apr; 19(2):93-99. doi: 10.1080/14764172.2016.1248440. Epub 2017 Jan 25.

69. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol. 2009 Sep-Oct; 26(5):547-50. doi: 10.1111/j.1525-1470.2009.00980.x.

70. Darwin E., Arora H., Hirt P.A. et al. A review of monochromatic light devices for the treatment of alopecia areata. Lasers Med Sci. 2018 Feb; 33(2):435-444. doi: 10.1007/s10103-017-2412-6. Epub 2017 Dec 17.

71. Trink A., Sorbellini E., Bezzola P. et al. A randomized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013; 169:690–4.
72. Sukhbir Singh. Role of platelet-rich plasma in chronic alopecia areata: Our centre experience. Indian J Plast Surg. 2015 Jan-Apr; 48(1): 57–59. doi: 10.4103/0970-0358.155271